|
AD Connect
User
Home
Discussions
Datasets
Tech Help
Events
Video Library
FDSA
Datasets
Datasets
Datasets
Forums
Tags
More
Cancel
New
Dataset Categories Navigation
-
Datasets
+
Region
+
Clinical Trial
-
Data Type
+
Disease
Clinical
Gene Expression
+
Imaging
+
Immunoassay
Placebo
+
Sequence
Synthetic
Datasets
Datasets
Data Type
Datasets
A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective...
This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated…
A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone on cognition in subjects with mild to moderate Alzheimer's disease
What is it and what does it include? This phase II study was designed to determine the safety profile and treatment effects of rosiglitazone (RSG) in subjects with mild to moderate Alzheimer’s disease…
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease
What is it and what does it include? This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's. This…
A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with...
What is it and what does it include? This phase I interventional study assesses single and repeat doses of GSK933776 (a Beta-amyloid (Aβ) antibody) in patients with Alzheimer's disease. A total of 50…
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease
What is it and what does it include? The study included 124 people between the ages of 50 and 80 with mild to moderate Alzheimer's disease and compared 250 mg of Rilapladib taken once daily to placebo…
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is…
